Shire sells eight 'non-core' products for $213 million

Share this article:

Shire said today that it is selling eight “non-core” products to Spanish company Almirall for $213 million.

“The divested products are no longer core to Shire's strategy of building market leading positions in specialty markets,” the company said in a statement.

Shire said its focus is moving forward will be on building its attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal and renal diseases businesses and, with its recent in-licensing of Juvista (human recombinant), to build a new specialty area of regenerative medicine.

There are eight products being sold in the transaction. They include:

* Lodine (etodolac) for treatment of rheumatoid arthritis.

* Colazide (balsalazide) for treatment of mild to active ulcerative colitis.

* Meptid (meptazinol hydrochloride) for treatment of pain.

*Cebutid (flurbiprofen) for treatment of the symptoms of rheumatoid arthritis and osteoarthritis.

*Robaxin (methocarbamol) for relief of pain from muscle injuries, spasms, sprains and strains.

*Mintec (peppermint oil) for the relief of discomfort associated with irritable bowel syndrome.

*Solaraze (diclofenac sodium) is a topical preparation for the treatment of actinic keratoses.

*Vaniqa (eflornithine) is a topical prescription medicine for treating unwanted facial hair in women.
 
Almirall chairman and CEO Jorge Gallardo said in a statement the acquisition would expand his company's international presence and “reinforces our position as one of the key European specialty pharmaceutical companies.”

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions